Novo Nordisk registers Phase 3 cardiovascular outcomes trial for zenagamtide, acronym AMBIENCE

- The trial, registered under NCT07861100 with sponsor ID NN9490-8037 and acronym AMBIENCE, is listed with an estimated enrollment of 8500 participants and status "not yet recruiting." Its primary endpoint is time.

The trial, registered under NCT07861100 with sponsor ID NN9490-8037 and acronym AMBIENCE, is listed with an estimated enrollment of 8500 participants¹ and status "not yet recruiting." Its primary endpoint is time from randomization to first occurrence of a 4-point composite major adverse cardiovascular events (MACE) endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke, and HF hospitalization or urgent HF visit.¹ The record lists an estimated start date of 2026-10-26 and estimated primary completion of 2030-09-16.

Fact check notes

Checker's noteThe claim that Novo Nordisk 'registered one new Phase 3 study this period' introduces an unverifiable framing about registration volume/timeframe that is not supported by the single trial record provided.
Sentence removedNovo Nordisk A/S registered one new Phase 3 study this period, with a first-posted date of 2026-10-06.unsupported: The first-posted date matches, but the source provides no information about how many studies Novo Nordisk registered 'this period' or that this is the only one; that framing is not supported by the single record provided.
Sentence removedZenagamtide, Phase 3, cardiovascular risk and obesity: the study evaluates the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.